Aurinia Pharmaceuticals Inc. today announced robust financial results for the three and six months ended June 30, 2025, demonstrating continued strong performance. Net product sales for LUPKYNIS in Q2 2025 reached $66.574 million, an increase from $55.028 million in Q2 2024. Total revenue for the quarter was $70.008 million, up from $57.192 million in the prior year period.
The company reported a significant increase in profitability, with net income of $21.513 million, or $0.16 diluted earnings per share, for Q2 2025, compared to $0.722 million, or $0.01 diluted earnings per share, in Q2 2024. For the first six months of 2025, net cash provided by operating activities was $45.541 million, a substantial improvement from an outflow of $(2.755) million in the same period of 2024. Excluding restructuring-related payments, operating cash flow for the first half of 2025 was $57.0 million.
Aurinia is increasing its full-year 2025 total revenue guidance from a range of $250 million to $260 million to a new range of $260 million to $270 million. Net product sales guidance was also raised from $240 million to $250 million to a new range of $250 million to $260 million. The Board of Directors approved an additional $150 million increase to the share repurchase plan, bringing total repurchases to 18.3 million common shares for $138.4 million since February 21, 2024. As of June 30, 2025, the company held $315.1 million in cash, cash equivalents, restricted cash, and investments.
The company's strong performance is partially driven by the new 2024 American College of Rheumatology lupus nephritis treatment guidelines, which recommend LUPKYNIS for first-line therapy. Operational efficiency improvements from the November 2024 restructuring continue to yield benefits, with selling, general, and administrative expenses falling from $44.9 million in Q2 2024 to $26.0 million in Q2 2025, and the restructuring remaining on pace for about $40 million in annualized savings.
Aurinia also highlighted positive results from its Phase 1 study of aritinercept (AUR200), a dual inhibitor of BAFF and APRIL. Aritinercept was well tolerated at all tested dose levels, and single doses led to robust and long-lasting reductions in immunoglobulins. The company plans to initiate clinical studies for AUR200 in at least two autoimmune diseases in the second half of 2025, further advancing its pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.